awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q39090350-E527CAFF-C7AB-4B81-AF7D-768492F8BD5D
Q39090350-E527CAFF-C7AB-4B81-AF7D-768492F8BD5D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q39090350-E527CAFF-C7AB-4B81-AF7D-768492F8BD5D
Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study.
P2860
Q39090350-E527CAFF-C7AB-4B81-AF7D-768492F8BD5D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q39090350-E527CAFF-C7AB-4B81-AF7D-768492F8BD5D
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
e962cfe40c5ee0e3ce089666404372666a9030b6
P2860
A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the Nati